References
- Engelman JA. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550–62
- Garner RC. (2010). Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2:429–40
- Garner RC, Goris I, Laenen AA, et al. (2002). Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 30:823–30
- Gibbons JJ, Abraham RT, Yu K. (2009). Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 36:S3–17
- Graham RA, Lum BL, Morrison G, et al. (2011). A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 39:1460–7
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13
- Hop CE, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3
- Kim DH, Sarbassov DD, Ali SM, et al. (2002). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163–75
- Lappin G, Seymour M. (2010). Addressing metabolite safety during first-in-man studies using (1)(4)C-labeled drug and accelerator mass spectrometry. Bioanalysis 2:1315–24
- Lappin G, Stevens L. (2008). Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol 4:1021–33
- Lin TH, Hu K, Flarakos J, et al. (2013). Assessment of the absorption, metabolism and excretion of [(1)(4)C]pasireotide in healthy volunteers using accelerator mass spectrometry. Cancer Chemother Pharmacol 72:181–8
- Mortensen DS, Fultz KE, Xu S, et al. (2015). CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization. Mol Cancer Ther 14:1295–305
- Ognibene TJ, Bench G, Vogel JS, et al. (2003). A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal Chem 75:2192–6
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–101
- Sharma R, Litchfield J, Bergman A, et al. (2015). Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment. Drug Metab Dispos 43:190–8
- Tse S, Leung L, Raje S, et al. (2014). Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry. Drug Metab Dispos 42:2023–32
- Vivanco I, Sawyers CL. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501